Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B vaccine responsiveness in children with autism
IRCT20130904014562N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Responsiveness rate to hepatitis B vaccine in children with autism, Antibody durability and 4 more. Started Feb 2017; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on IRCT20130904014562N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130904014562N2.